Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Tipifarnib · NSC-702818, R-11577

Small molecule · Inhibitor of farnesyl protein transferase (FNTA) · developed by Kura Oncology

Phase 1/2 Most advanced trial (none active)
KURA Developer
1 Registered trials

What is Tipifarnib?

Tipifarnib is a nonpeptidomimetic quinolinone that binds and inhibits farnesyl protein transferase, blocking protein farnesylation needed for Ras signal transduction. It is studied in squamous cell carcinoma of the head and neck.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NSC-702818, R-11577, R-115777
Drug type
Small molecule
Targets
farnesyl protein transferase (FNTA)
Mechanism
Inhibitor of farnesyl protein transferase (FNTA)
Pathways
Ras farnesylation and signal transduction, apoptosis, angiogenesis
Therapy area
Oncology
Developer
Kura Oncology, Inc. (KURA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
MAT637500A

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT04997902 Phase 1/2 HNSCC Completed KURA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

HNSCC

Other drugs acting on FNTA

More from Kura Oncology

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the KURA page.

Follow KURA, the company behind Tipifarnib

See KURA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KURA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.